KNOWLEDGE, ATTITUDE AND PRACTICE OF YEMENI PHYSICIANS TOWARD PHARMACOVIGILANCE: A MIXED METHOD STUDY

YASER MOHAMMED AL-WORAFI1,2*
1College of Pharmacy, University of Science and Technology, Yemen, 2College of Pharmacy, Ajman University, UAE
Email: yworafi@yahoo.com

Received: 19 May 2018 Revised and Accepted: 03 Sep 2018

ABSTRACT

Objective: The objective of the current study was to investigate the physician's knowledge, attitude and practice towards pharmacovigilance.

Methods: A mixed qualitative and quantitative method was conducted in this study using a face to face questionnaire among the physicians in the capital Sana'a, Yemen.

Results: Of the 105 respondents (79 %) were male. Participants age mean was 35.55±4.45 y. Majority of physicians (73.3 %) had a moderate knowledge towards pharmacovigilance; (15.2 %) had a good knowledge and (11.4 %) had a poor knowledge. 35 (33.3 %) physicians were seen adverse drug reactions (ADRs) happened to their patients. Allergy was the most common ADRs. However, no ADR was reported. 66.7 % of physicians had a positive attitude towards pharmacovigilance. The most barriers reported by physicians were: lack of motivation and lack of knowledge about reporting system. Reported factors to encourage ADRs reporting were: attend courses or workshops; educational materials and simplification of reporting procedures.

Conclusion: Majority of physicians in Sana'a, Yemen had moderate knowledge and positive attitude towards pharmacovigilance. Educational and training programmes are the cornerstone of improving ADRs reporting in Yemen.

Keywords: Pharmacovigilance, Knowledge, Attitude, Physicians and Yemen

INTRODUCTION

Pharmacovigilance science and activities are necessary for the safety and efficacy of medications [1]. Pharmacovigilance activities worldwide play very important role to ensure the rationality as well as safety of medicines and herbal medications which improve the cost-effectiveness [1-4]. One of the most important activities of pharmacovigilance is adverse drug reactions (ADRs) reporting [2,9]. Pharmacovigilance defined by World Health Organization (WHO) decades ago as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems” [1] ADRs defined by WHO as “any noxious, unintended, and undesired effect that occurs as a result of treatment with drug at a normal doses used in man for diagnosis, prophylaxis, and treatment” [5]. ADRs reported as an important cause of patient’s morbidity and mortality, admissions to the hospitals and increase the length of hospitalization as well as the cost of management [6-10]. Yemeni Pharmacovigilance Center (YPVC) was established on the capital Sana’a in early 2011 with the following aims and objectives; “early detection of adverse drug reactions (ADRs); detection of increase in frequency of (known) adverse reaction; identification of risk factors and possible mechanisms underlying adverse reactions; estimation of quantitative aspects of benefit/risk analysis and dissemination of information needed to improve drug prescribing and regulation; prevention of adverse drug reactions; drug quality surveillance; encouraging rational and safe use of drugs and communication with international institutions working in pharmacovigilance” [11, 12]. The role of physicians is very important in reporting ADRs [13, 14]. Therefore, the aim of this study was to investigate the knowledge, attitude and barriers of Yemeni physicians towards pharmacovigilance, ADRs and ADRs reporting.

MATERIALS AND METHODS

Study design and study duration

A cross-sectional study was conducted over a period of four months (1st August to 30th November 2016) among Physicians in Sana’a, Yemen. Sample size

According to the annual reports of the Ministry of Public Health and Population 2014 the numbers of physicians are 1732 in the capital Sana’a [15]. Based on this statistics 315 physicians were selected conveniently from each region in the capital Sana’a to have an estimate of precision at the 95% confidence interval (CI), with an α = 0.05.

Study tools

A mixed qualitative and quantitative method was conducted in this study using a face to face questionnaire. The questionnaire was developed based on the information from the literature [16-18]. The questionnaire was pilot tested on a convenience sample of ten physicians in Ibb city to test the validity of the survey form. The final questionnaire was composed of six sections. Scoring system was used in this study to assess the knowledge and attitude of physicians in Yemen towards pharmacovigilance, ADRs and ADRs reporting. A score of 1 and 0 was given for each correct and wrong answer respectively, the answer was considered correct if the participant answered correctly or nearly to the correct answer. Total scores were calculated for each participant. A maximum 10 score were for evaluation the knowledge. A score equal to and greater than 6 was considered as good knowledge, scores 5 and 4 was considered as moderate knowledge, score less than 4 were considered as poor knowledge.

Four levels Likert scaling (A: agree. SA: strongly agree. D: disagree and SD: strongly disagree.)

Was used to explore the attitude, barriers and factors will encourage physicians in Yemen to report ADRs. A maximum 10 score were for evaluation the attitude. A score of 1 and 0 was given for each positive and negative answer respectively. Total scores were calculated for each participant. A score greater than or equal to 6 was considered as positive attitude, score less than 6 were considered as negative attitude. Tow trained pharmacists were conducted this study by visiting physicians at their clinics or working hospitals.
Ethical approval
This study was approved from University of Science and Technology, Yemen. Furthermore, written consent was also taken from the respondents. Questions that may related the personal information were avoided.

Statistical analysis
Data were entered and analysed using SPSS version 21 (SPSS Statistics for Windows, version 21.0, IBM Corp., USA). Differences in proportional were tested with Chi-square test or Fisher’s exact test. Differences in the means were test with the student t-test. All reported p-values are two tailed, and the result is significant if P-value is ≤ 0.05.

RESULTS
A total of 400 physicians were interviewed. However only 105 questionnaires were completed and analyzed. The mean age of the respondents was found to be 35.55±4.54 y. The characteristics of the study sample are presented in table 1.

Table 1: Sociodemographic characteristics of the physicians

| Variable               | Frequency (%) |
|------------------------|---------------|
| Gender                 |               |
| Male                   | 83 (79%)      |
| Female                 | 22 (21%)      |
| Qualifications         |               |
| Bachelor               | 4 (3.8%)      |
| Higher                 | 101 (96.2%)   |
| Workplace              |               |
| Hospital               | 26 (24.8%)    |
| Clinic                 | 79 (75.2%)    |
| Rank                   |               |
| General practitioner   | 4 (3.8%)      |
| Specialist             | 83 (79%)      |
| Consultant             | 18 (17%)      |
| Experience years       |               |
| less than 5            | 10 (9.5%)     |
| 5-10                   | 64 (61%)      |
| 11-20                  | 25 (23.8%)    |
| More than 20           | 6 (5.7%)      |
| Graduation country     |               |
| Yemen                  | 26 (24.8%)    |
| Others                 | 79 (75.2%)    |

Table 2: Knowledge related questions (correct answers)

| Statement                                      | Frequency (%) |
|------------------------------------------------|---------------|
| What is Pharmacovigilance?                    | 94 (89.5%)    |
| What is an Adverse Drug Reaction (ADR)?       | 95 (90 %)     |
| How does an ADR differ from a side effect?    | 89 (84.8%)    |
| What are the types of ADRs?                   | 11 (10.5%)    |
| Why is pharmacovigilance important?           | 93 (88.6%)    |
| Who should report ADRs?                       | 17 (16.2%)    |
| How the report an adverse drug reaction can be done? | 17 (16.2%) |
| When the pharmacovigilance centre in Yemen was established? | 3 (2.9%) |
| Where is the location of pharmacovigilance Centre in Yemen? | 3 (2.9%) |
| What is the objectives of pharmacovigilance centre in Yemen? | 1 (1%) |
| Total scores: mean±(SD)                       | 4.03±1.60     |
| Knowledge                                      |               |
| Good knowledge                                 | 16 (15.2%)    |
| Moderate knowledge                             | 77 (73.3%)    |
| Poor knowledge                                 | 12 (11.4%)    |

Knowledge of physicians about pharmacovigilance, ADRs and ADRs reporting in Yemen
The finding of this study showed that there were no significant association between the good knowledge and other factors (P-value=0.05).
Table 2 shows the knowledge of physicians towards pharmacovigilance, ADRs and ADRs reporting.

Experience of yemeni physicians with adverse drug reactions (ADRs) and its reporting
The finding of this study showed that there were 35 (33.3 %) physicians were detected and seen ADRs in their practice. The most common ADRs they detected were allergy. However they didn’t report any ADR.

Attitude of Yemeni physicians towards pharmacovigilance and adverse drug reactions (ADRs) reporting
The finding of this study showed that there were no significant association between the positive attitude and other factors (P-value=0.05).
Table 3 shows the attitude of physicians towards pharmacovigilance, ADRs and ADRs reporting.

Barriers of adverse drug reactions (ADRs) reporting
Table 4 shows the barriers of ADRs reporting.
identify the required interventions to improve ADRs reporting. The reporting in Yemen. This issue is very important to research in order to barriers of physicians toward pharmacovigilance, ADRs and ADRs. This study aimed to explore the knowledge, attitude, practice and DISCUSSION
Factors encourage adverse drug reactions (ADRs) reporting
Table 5 shows the factors encourage ADRs reporting.

Table 3: Attitude related questions (Positive attitude)

| Statement                                                                 | Frequency (%) |
|---------------------------------------------------------------------------|---------------|
| I believe that pharmacovigilance is important                             | 101 (96.2 %)  |
| Reporting ADRs is part of the professional role                           | 96 (81.9 %)   |
| I want to be sure the ADR is related to the drug before reporting         | 63 (60 %)     |
| I report an ADR that causes:                                              |               |
| a. hospitalisation                                                        | 69 (65.7 %)   |
| b. a life threatening situation                                           | 69 (65.7 %)   |
| c. a congenital anomaly                                                   | 69 (65.7 %)   |
| d. persistent disability or incapacity                                    | 72 (68.6 %)   |
| e. death of the patient                                                   | 43 (41 %)     |
| I report to get more insight into ADR questions that I come across in my practice | 8 (7.6 %)     |
| I report to show the patient that their concern is being taken seriously  | 45 (42.9 %)   |
| Total scores: mean±SD                                                    | 5.95±3.23     |
| Positive attitude                                                         | 70 (66.7 %)   |

Table 4: Barriers of adverse drug reactions (ADRs) reporting

| Barrier                                                                 | Frequency (%) |
|------------------------------------------------------------------------|---------------|
| I don’t report ADR because reporting form not available                | 15 (14.3 %)   |
| I don’t report ADR because I don’t know the address where these reports should be sent | 16 (15.2 %)   |
| The reporting form too complicated                                     | 17 (16.2 %)   |
| Reporting ADRs is time consuming                                       | 14 (13.3 %)   |
| All serious ADRs are detected before registration                      | 5 (4.8 %)     |
| I don’t report ADR because I want to publish about them myself         | 2 (1.9 %)     |
| I don’t report ADR because I am not convinced about the confidential handling of the reports | 9 (8.6 %)     |
| I don’t report ADR because I fear it may harm the confidence of my patients | 20 (19 %)     |
| I don’t report because I find it difficult to admit that the patients has been harmed | 3 (2.9 %)     |
| I don’t report because reporting may give the impression that I am ignorant concerning ADRs | 3 (2.9 %)     |
| I don’t report because I fear legal liability for the reported ADRs    | 4 (3.8 %)     |
| I am not motivated to report                                           | 105 (100 %)   |
| I don’t report because I have insufficient clinical knowledge          | 4 (3.8 %)     |
| I don’t report because I don’t know how to report ADR                  | 86 (66.7 %)   |
| I don’t report because I am not convinced the ADR is caused by the drug | 70 (38.1 %)   |

Table 5: Factors encourage adverse drug reactions (ADRs) reporting

| Factors                                                                 | Frequency (%) |
|------------------------------------------------------------------------|---------------|
| I will report if:                                                      |               |
| 1. attend course or workshops to understand the reporting process       | 68 (64.2 %)   |
| 2. receive materials to understand the reporting process               | 77 (72.6 %)   |
| 3. More attention to ADR reporting in university curriculum            | 88 (83 %)     |
| 4. simplification of reporting procedure                               | 69 (65.1 %)   |
| 5. promoting reporting as a part of professional duty                  | 13 (12.3 %)   |
| 6. there is a fee                                                      | 89 (94 %)     |
| 7. I receive more feedback through mailings                            | 39 (36.8 %)   |
| 8. compulsory reporting                                                 | 43 (40.6 %)   |

Factors encourage adverse drug reactions (ADRs) reporting
Table 5 shows the factors encourage ADRs reporting.

DISCUSSION
This study aimed to explore the knowledge, attitude, practice and barriers of physicians toward pharmacovigilance, ADRs and ADRs reporting in Yemen. This issue is very important in research in order to identify the required interventions to improve the ADRs reporting. The concept of pharmacovigilance in Yemen is new as the Yemeni Pharmacovigilance Center (YPVC) was established in early 2011 [11, 12]. Majority of physicians (73.3 %) had a moderate knowledge towards pharmacovigilance, ADRs and ADRs reporting; (15.2 %) had a good knowledge and (11.4 %) had a poor knowledge. Majority of physicians couldn’t have answered the questions related to ADRs reporting system and Yemeni pharmacovigilance system, while they answered correctly questions related to the pharmacovigilance and ADRs. There is a difference between the findings of this study and the previous studies in terms of knowledge [19-23]. This is could be due to that Yemeni Pharmacovigilance Center (YPVC) was established on the capital Sana’a in early 2011 and faced challenges in reporting and marketing its activities [11, 12, 24].

The finding of this study showed that there were 35 (33.3 %) physicians were detected and seen ADRs in their practice. The most common ADRs they detected were allergy. However they didn’t report any ADR. There was a difference between this study and the previous studies [19-23] in terms of experience of reporting ADRs. They showed that the factors to encourage ADRs reporting were: attend course or workshops; educational materials and simplification of reporting procedure. ADRs could harm the patients and could be minimized by increasing the awareness of health care professionals about it [25].
CONCLUSION

The present study showed that the majority of physicians in Sana’a, Yemen had moderate knowledge about pharmacovigilance, ADRs and its reporting. They had a poor knowledge towards ADRs reporting. Physicians should take their responsibility towards pharmacovigilance. Education and training are the cornerstone of improving ADRs reporting in Yemen. The current study had several limitations: This study was conducted in the capital Sana’a only therefore; the findings cannot be generalized to other cities.

RECOMMENDATIONS

Future studies in other cities are highly recommended. Increase the awareness about pharmacovigilance and ADRs reporting among physicians as well as other health care professionals are highly recommended. Training and educational programmes are highly recommended to improve the ADRs reporting.

ACKNOWLEDGEMENTS

I would like to thank the participants in this study

CONFLICT OF INTERESTS

There is no conflict of interest

REFERENCES

1. WHO publications. The importance of pharmacovigilance: safety monitoring of medicinal products. WHO Collaborating Centre for International Drug Monitoring. Geneva, Switzerland; 2002.
2. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool. 2006. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficiency/Pharmacovigilance_Brochure.pdf [Last accessed on 10 Apr 2018]
3. Hazell IL, Shakir SA. Under-reporting of adverse drug reactions. Drug safety 2006;29:385-96.
4. Härmark L, Van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.
5. World Health Organization. International drug monitoring: the role of national centres, report of a WHO meeting. 1971. Available from: http://apps.who.int/iris/handle/10665/49068. [Last accessed on 10 Apr 2018] 6. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. Br Med J 1998;316:1295–8.
7. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832–40.
8. Pirmohamed M, James S, Maakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15–9.
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
10. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
11. Yemeni Pharmacovigilance Center (YPVC). 2014. Available from: http://www.ypvc-sbd.com. [Last accessed on 01 May 2014]
12. Al-Worafi YM. Comment on: pharmacovigilance in the middle East. Drug Safety 2014;37:651.
13. Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ, Green M, Andrews LG, et al. Physician reporting of adverse drug reactions. JAMA 1990;263:1785-8.
14. Cosentino M, Leoni O, Diana F, Lucumi S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. PharmacoI Res 1997;35:85-8.
15. Ministry of Public Health and Population. Annual statistical health report; 2014. Available from: http://www.mophp-ye.org/arabic/docs/Report2014.pdf [Last accessed on 10 Apr 2018]
16. Pharmacovigilance guideline. World Health Organization. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficiency/SAfricaDraftGuidelines.pdf [Last accessed on 10 Apr 2018]
17. Al-Worafi YM, Kassab YW, Alseragi WM, Almutairi MS, Ahmed A, Ming LC, et al. Pharmacovigilance and adverse drug reaction reporting: a perspective of community pharmacists and pharmacy technicians in sana’a, Yemen. Ther Clin Risk Management 2017;13:1175.
18. Van Grootheest AC, Mes K, De Jong-Van, Den Berg LTW. Attitudes of community pharmacists in the Netherlands towards adverse drug reaction reporting. Int J Pharm Practice 2002;10:267-72.
19. Abdel-Latif MM, Abdel-Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharm J 2013;21:523-61.
20. Ifet W, Shaheel S, Rahim N, Anjum F, Nesar S, Ghayas S. Pakistani physicians knowledge and attitude towards reporting adverse drug reactions. Afr J Pharm Pharmacol 2014;8:379-85.
21. Adeeji WA, Ibraheem WA, Fehintola FA. Attitude and practice of doctors toward adverse drug reactions (ADRs) reporting in a Nigerian tertiary health facility. Annals Ibadan Postgraduate Med 2013;11:77-80.
22. Lopez Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Safety 2009;32:19-31.
23. Agarwai R, Daher AM, Ismail NM. Knowledge, practices and attitudes towards adverse drug reaction reporting by private practitioners from Klang Valley in Malaysia. Malaysian J Med Sci 2013;20:52.
24. Al-Worafi YM. Pharmacy practice in Yemen. In: Pharmacy Practice in Developing Countries: Achievements and Challenges; 2016. p. 267–87.
25. Raut AS, Pawar AT, Pankaj MA, Srivastava PR, Mishra AD. Clinical pattern and severity of cutaneous adverse drug reactions. Int J Pharm Pharm Sci 2013;5;6:12-6.